NCT Number: NCT00362531
Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome
Idiopathic membranous nephropathy (IMN) is one of the most common forms of nephrotic syndrome (NS) in adults and is usually treated by corticosteroids in combination with cytotoxic drugs especially cyclophosphamide or cyclosporine. Tacrolimus, a new immunosuppressive agent, was proved to be effective in treating refractory NS. Whether it is effective in IMN has not been reported. We therefore undertook a multi-center, controlled study to investigate the efficacy and safety profile of tacrolimus compared with cyclophosphamide in the treatment of patients with idiopathic membranous nephropathy and nephrotic syndrome.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2 / Phase 3
About this study
Idiopathic membranous nephropathy (IMN) is one of the most common forms of nephrotic syndrome (NS) in adults and is usually treated by corticosteroids in combination with cytotoxic drugs especially cyclophosphamide or cyclosporine. However, the effect was not satisfying and the side-effects of the above immunosuppressive agents were often a worrying problem. Tacrolimus, a new immunosuppressive agent, was proved to be effective in treating refractory NS especially FSGS. Whether it is effective in IMN has not been reported. We therefore undertook a multi-center, controlled study to investigate the efficacy and safety profile of tacrolimus compared with cyclophosphamide in the treatment of patients with idiopathic membranous nephropathy and nephrotic syndrome.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- All patients were diagnosed as idiopathic membranous nephropathy according to renal histology, with nephrotic syndrome, serum creatinine less than 2.5mg/dL, 18~70 years old, signed the informed consent and willing to be followed up according to the protocol.
Exclusion criteria
- Patients who had received immunosuppressive therapy within the previous 3 months, complicated other severe renal diseases, serum creatinine higher than 2.5mg/dL, severe infection, diabetes mellitus, liver disease, pregnancy, lactating, and anticipated poor compliance with the protocol.
Treatment and study plan
Primary outcomes
-
complete remission of renal disease at 12 months
Secondary outcomes
-
partial remission at 12 months and adverse events
Sponsors and collaborators
Lead sponsor
Peking University
Other
Registry information
Official study title
Phase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome
Important dates
- Study start
- 2004
- Study completion
- 2007
- First posted
- Aug 10, 2006
- Registry last updated
- Aug 10, 2006
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Personalized Medicine for Membranous Nephropathy
NCT03804359
Autoimmune Diseases, Female Urogenital Diseases
Amiens, France
View Trial DetailsActhar for Treatment of Proteinuria in Membranous Nephropathy Patients
NCT01386554
Autoimmune Diseases, Female Urogenital Diseases
Sacramento, California, United States
View Trial DetailsClinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy
NCT01845688
Autoimmune Diseases, Female Urogenital Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsEvaluate Rituximab Treatment for Idiopathic Membranous Nephropathy
NCT01508468
Autoimmune Diseases, Female Urogenital Diseases
Paris, France
View Trial Details